CRISPR Therapeutics AG (CRSP) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 1.46M | 864K | 889K | 892K | 865K | 35M | 602K | 517K | 504K | 200M | 0 | 70M |
| Revenue Growth % | 68.55% | -97.53% | 47.67% | 72.53% | 71.63% | -82.5% | - | -99.26% | -99.5% | 3333233.33% | -100% | 44203.8% |
| Cost of Goods Sold | 50.25M | 59.36M | 64.69M | 49.75M | 57.51M | 0 | 15.95M | 56.98M | 51.8M | 20M | 23.42M | 44.64M |
| COGS % of Revenue | 3446.43% | 6870.83% | 7277.05% | 5577.69% | 6648.44% | - | 2650% | 11020.5% | 10277.58% | 10% | - | 63.77% |
| Gross Profit | -48.79M | -58.5M | -63.8M | -48.86M | -56.64M | 35M | -15.35M | -56.46M | -51.3M | 180M | -23.42M | 25.36M |
| Gross Margin % | -3346.43% | -6770.83% | -7177.05% | -5477.69% | -6548.44% | 100% | -2550% | -10920.5% | -10177.58% | 90% | - | 36.23% |
| Gross Profit Growth % | 13.86% | -267.14% | -315.63% | 13.46% | -10.43% | -80.56% | 34.46% | -322.6% | -188.73% | 2740.46% | 39.58% | 175.12% |
| Operating Expenses | 81.46M | 96.26M | 68.25M | 84.21M | 91.78M | 99.59M | 94.78M | 94.8M | 89.29M | 110.42M | 108.99M | 120.59M |
| OpEx % of Revenue | 5586.9% | 11141.67% | 7677.73% | 9440.58% | 10610.4% | 284.54% | 15744.02% | 18336.75% | 17716.67% | 55.21% | - | 172.27% |
| Selling, General & Admin | 17.18M | 18.4M | 16.93M | 18.92M | 19.3M | 18.12M | 17.42M | 19.48M | 17.95M | 16.48M | 18.29M | 19.03M |
| SG&A % of Revenue | 1178.53% | 2129.51% | 1904.5% | 2120.63% | 2230.75% | 51.78% | 2893.52% | 3768.09% | 3562.1% | 8.24% | - | 27.19% |
| Research & Development | 68.57M | 77.86M | 58.9M | 65.29M | 72.48M | 82.16M | 77.36M | 75.32M | 71.34M | 95.14M | 90.7M | 101.56M |
| R&D % of Revenue | 4703.29% | 9012.15% | 6625.65% | 7319.96% | 8379.65% | 234.73% | 12850.5% | 14568.67% | 14154.56% | 47.57% | - | 145.08% |
| Other Operating Expenses | -1000K | 0 | -1000K | 0 | 0 | -691K | 0 | 0 | 0 | -1000K | 0 | 0 |
| Operating Income | -130.25M | -154.76M | -132.06M | -133.07M | -148.42M | -64.59M | -110.13M | -151.26M | -140.59M | 69.58M | -132.41M | -95.22M |
| Operating Margin % | -8933.33% | -17912.5% | -14854.78% | -14918.27% | -17158.84% | -184.54% | -18294.02% | -29257.25% | -27894.25% | 34.79% | - | -136.03% |
| Operating Income Growth % | 12.25% | -139.62% | -19.91% | 12.03% | -5.57% | -192.82% | 16.83% | -58.85% | -118.01% | 152.9% | 27.4% | 48.04% |
| EBITDA | -125.93M | -149.1M | -127.63M | -128.47M | -143.69M | -59.75M | -105.39M | -146.41M | -135.75M | 74.48M | -127.49M | -90.26M |
| EBITDA Margin % | -8637.11% | -17257.29% | -14356.13% | -14402.58% | -16611.33% | -170.7% | -17506.81% | -28320.12% | -26935.32% | 37.24% | - | -128.95% |
| EBITDA Growth % | 12.36% | -149.56% | -21.1% | 12.26% | -5.84% | -180.21% | 17.33% | -62.21% | -128.4% | 159.26% | 28.12% | 48.71% |
| D&A (Non-Cash Add-back) | 4.32M | 5.66M | 4.43M | 4.6M | 4.74M | 4.84M | 4.74M | 4.84M | 4.83M | 4.9M | 4.92M | 4.96M |
| EBIT | -130.25M | -154.76M | -105.82M | -133.07M | -148.42M | -64.59M | -110.13M | -151.26M | -140.59M | 69.58M | -132.41M | -95.22M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Other Income/Expense | 8.16M | 24.77M | 26.24M | -74.19M | 13.54M | 27.98M | 25.06M | 26.14M | 24.72M | 20M | 20.67M | 18.41M |
| Pretax Income | -122.09M | -130M | -105.82M | -207.26M | -134.89M | -36.61M | -85.07M | -125.12M | -115.87M | 89.58M | -111.74M | -76.82M |
| Pretax Margin % | -8373.94% | -15046.18% | -11903.49% | -23235.09% | -15593.87% | -104.6% | -14130.56% | -24201.35% | -22989.48% | 44.79% | - | -109.74% |
| Income Tax | 839K | 614K | 619K | 1.29M | 1.11M | 700K | 876K | 1.29M | 724K | 233K | 412K | 923K |
| Effective Tax Rate % | -0.69% | -0.47% | -0.58% | -0.62% | -0.82% | -1.91% | -1.03% | -1.03% | -0.62% | 0.26% | -0.37% | -1.2% |
| Net Income | -122.93M | -130.61M | -106.44M | -208.55M | -136M | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M | -112.15M | -77.74M |
| Net Margin % | -8431.48% | -15117.25% | -11973.12% | -23379.93% | -15722.08% | -106.6% | -14276.08% | -24450.29% | -23133.13% | 44.67% | - | -111.06% |
| Net Income Growth % | 9.61% | -250.07% | -23.85% | -64.98% | -16.64% | -141.76% | 23.37% | -62.6% | -119.71% | 180.8% | 35.75% | 58.17% |
| Net Income (Continuing) | -122.93M | -130.61M | -106.44M | -208.55M | -136M | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M | -112.15M | -77.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.28 | -1.37 | -1.17 | -2.40 | -1.58 | -0.44 | -1.01 | -1.49 | -1.43 | 1.10 | -1.41 | -0.98 |
| EPS Growth % | 18.99% | -211.36% | -15.84% | -61.07% | -10.49% | -140% | 28.37% | -52.04% | -113.43% | 178.01% | 37.05% | 59.17% |
| EPS (Basic) | -1.28 | -1.37 | -1.17 | -2.40 | -1.58 | -0.44 | -1.01 | -1.49 | -1.43 | 1.12 | -1.41 | -0.98 |
| Diluted Shares Outstanding | 96.05M | 89.93M | 91.31M | 87.07M | 85.94M | 85.46M | 85.23M | 84.92M | 81.79M | 81.32M | 79.41M | 79.09M |
| Basic Shares Outstanding | 96.05M | 89.93M | 91.31M | 87.07M | 85.94M | 85.46M | 85.23M | 84.92M | 81.79M | 79.69M | 79.41M | 79.09M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |